On the recordJuly 20, 2004
The problem with E is that it costs a little more money than the others.
Source
congress.govThe problem with E is that it costs a little more money than the others.
Discussing the cost of effective drug treatment programs.
Share & report
More from Mike DeWine
vigorous antitrust enforcement we believe remains vitally important to ensuring that our markets function properly
I expect you to reach an agreement and submit your plans to the National Capital Planning Commission no later than March 3.
So I would maintain that one could argue that that figure that you cited is understated.